Fractyl Health to Present New Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Fractyl Health to Present New Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place December 12-14, 2024.
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place December 12-14, 2024.
Details of the session are below:
Details of the session are below:
- Poster Title: Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs
- Presentation Date & Time: Thursday, December 12, 2024, 6:30 pm - 7:30 pm (PST)
- Poster Title: Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs
- Presentation Date & Time: Thursday, December 12, 2024, 6:30 pm - 7:30 pm (PST)
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health's goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit or .
Fractyl Health是一家代謝治療公司，專注於開拓治療代謝疾病，包括肥胖和T2D的新方法。儘管在過去50年的治療方面已經取得進展，但肥胖和T2D仍然是21世紀快速增長的疾病和死亡原因。Fractyl Health的目標是將代謝性疾病治療從慢性症狀管理轉變爲針對疾病的根本原因的持久性病理治療方法。Fractyl Health總部位於馬薩諸塞州伯靈頓。有關更多信息，請訪問
Fractyl Health（臨時代碼）是一家專注於開拓治療代謝疾病新方法的代謝治療公司，包括肥胖和T2D。儘管在過去50年中治療方面取得了進展，但肥胖和T2D仍然是21世紀疾病和死亡率迅速增長的推動因素。Fractyl Health（臨時代碼）的目標是將代謝性疾病的治療從慢性症狀管理轉變爲針對疾病的器官水平根本原因的持久疾病修飾療法。Fractyl Health（臨時代碼）位於馬薩諸塞州伯靈頓。欲了解更多信息，請訪問 或 .
About Rejuva
Fractyl Health's Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.
關於Rejuva
Fractyl Health的Rejuva平台專注於開發下一代基於腺相關病毒（AAV）的局部輸送基因療法，用於治療肥胖和T2D。 Rejuva平台正處於臨床前階段開發，並尚未受到監管機構的調查或商業使用評估。 Rejuva利用先進的傳遞系統和專有的篩選方法來識別和開發靶向胰腺的新陳代謝活躍基因療法候選藥物。該計劃旨在通過提供旨在解決疾病潛在根本原因的新型、疾病修飾療法，改變代謝性疾病的管理。
Contacts
聯繫人
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800
公司聯繫方式
Lisa Davidson, 致富金融(臨時代碼) 首席財務官
ir@fractyl.com，781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622
媒體聯繫人
Jessica Cotrone, 公司通信
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Stephen Jasper Gilmartin Group
stephen@gilmartinir.com, 619.949.3681
投資者聯繫方式
斯蒂芬·賈斯珀·吉爾馬丁集團
stephen@gilmartinir.com, 619.949.3681